Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'Documents regarding endocrine disruptors DG TRADE'.






Ref. Ares(2016)696829 - 09/02/2016
Ref. Ares(2017)676538 - 07/02/2017
 
 
February 9, 2016 
 
Submitted via e-mail to EU TBT Enquiry Point 
 
ACC Comments on G/TBT/N/EU/329 
 
To whom it may Concern: 
 
The American Chemistry Council (ACC)1 appreciates the opportunity to provide the following 
comments on WTO TBT notification G/TBT/N/EU/329.  These comments express deep concern 
regarding the recent draft Decision communicated to the WTO from the European Commission 
to list four substances as Substances of Very High Concern (SVHC) on the basis of endocrine 
disruption.   This Decision applies to benzyl butyl phthalate (BBP), dibutyl Phthalate (DBP), bis-
(2-ethylhexyl) phthalate (DEHP), and diisobutyl phthalate (DIBP).  Specifically, each phthalate 
is proposed as a Substance of Very High Concern (SVHC) for inclusion the REACH Candidate 
List in accordance with Article 57 (f) of the REACH regulation on the basis of endocrine 
disrupting properties for which there is scientific evidence of probable serious effects to human 
health that give rise to an equivalent level of concern to those substances identified as 
carcinogenic, mutagenic and/or toxic to reproduction. 
 
These substances are already listed on the REACH Candidate List as SVHCs for reproductive 
effects (based on their classification as Category 1B under the EU Classification Labelling and 
Packaging Regulation). The reproductive effects are the adverse endocrine effects and in 
addition a threshold does apply for these effects as confirmed by the ECHA Risk Assessment 
Committee which has developed DNELs (Derived No Effect Levels) for these substances. Given 
the existing SVHC identification and listing already covers the adverse reproductive effects 
which may be related to an endocrine mechanism and for which there is data to show a threshold, 
a second listing as an endocrine disruptor for what are the same adverse effects is not justified or 
necessary. No new additional data relevant to human health (e.g. animals studies) are presented 
in the scientific reports that underlie this decision that were not in the detailed evaluation carried 
out by the ECHA Member State Committee (MSC) on DEHP and the other three LMW 
classified phthalates. No justification can be envisaged to subject a substance twice to Candidate 
Listing and Authorisation on the basis of the same health data. In addition the regulatory 
consequences of being listed on the Candidate List and Annex XIV are already being applied for 
these substances (requirement for Authorisation of uses; for DEHP and DBP Authorisation 
applications are in progress; for DBP and BBP no Authorisation applications have been made 
and all REACH regulated uses were phased out as of February 2015). It should also be noted that 
                                                           
1 The American Chemistry Council (ACC) represents the leading companies engaged in the business of chemistry. 
ACC members apply the science of chemistry to make innovative products and services that make people's lives 
better, healthier and safer. ACC is committed to improved environmental, health and safety performance through 
Responsible Care®, common sense advocacy designed to address major public policy issues, and health and 
environmental research and product testing. The business of chemistry is an $801 billion enterprise and a key 
element of the nation's economy. It is the nation’s largest exporter, accounting for fourteen percent of all U.S. 
exports. 
 
americanchemistry.com®                                  700 Second St., NE | Washington, DC | 20002 | (202) 249-7000                                                                       


there is no need to demonstrate equivalent level of concern when that level of concern is already 
agreed for the reproductive effects which are the adverse endocrine effects. 
 
In addition to the above points on regulatory duplication, the scientific validity of the 
conclusions is questionable as the evaluations (i.e. the Annex XV reports) failed to adhere to key 
principles of scientific inquiry for evaluating cause and effect for endocrine-mediated toxicity.  
According to the WHO/IPCS definition, an “endocrine disruptor” is “an exogenous substance or 
mixture that alters function(s) of the endocrine system and consequently causes adverse health 
effects in an intact organism, or its progeny, or (sub)populations.”  Therefore, for a substance to 
be concluded as an endocrine disruptor requires 1) evidence supporting endocrine activity; 2) 
evidence supporting an adverse effect; and 3) evidence supporting that the endocrine activity is 
the most likely explanation for the observed adverse effect and is causally related to the adverse 
health effects.  The Annex XV reports for these substances focused on only the first two 
considerations of this cited definition.  As such, the important distinction between endocrine 
active and endocrine disruptive was overlooked.  This distinction is significant because 
endocrine activity (i.e. a simple biological interaction) is not an adverse effect per se, but 
represents the biological mechanism that may lead to an adverse effect.  Therefore, an 
observation of endocrine activity in cell based systems or in whole animals is not on its own 
demonstration of endocrine disruption. Endocrine disruption only results when exposure to a 
substance goes beyond a simple interaction and results in an adverse health effect.   
 
Furthermore, a substance may lead to an adverse effect by a number of diverse biological 
pathways many of which are not endocrine-relevant. Therefore it is critical to determine if there 
are other data that suggest the substance is more likely to lead to an adverse effect through 
another, non-endocrine pathway (i.e. causality assessment). The internationally recognized Mode 
of Action/Human Relevance (MOA/HR) framework has been developed by the WHO/IPCS for 
this purpose.  Application of this framework or any type of systematic evaluation of the weight 
of evidence in support of a casual endocrine mode of action is not apparent in these Annex XV 
reports.  As such, these reports fail to objectively and transparently establish the evidence basis 
for a link between the purported endocrine activity and the adverse effects.  Additionally, there is 
no discussion of key considerations (potency, severity, threshold) important for establishing 
equivalent level of concern which is a clear requirement for an SVHC according to Article 57(f) 
of the REACH Regulation.  Considering the significant regulatory implications the Annex XV 
SVHC proposals have on the availability of a particular chemical in the market, the significant 
short-comings call into question the appropriateness of this approach for the identification of a 
substance of very high concern according to the criteria set out in REACH Article 57(f) on the 
basis of endocrine disruption. It should also be noted that in the Annex XV dossiers for the four 
substances it is often unclear whether cited effects are adverse, adaptive or non-adverse i.e. there 
is no clear definition of adversity being used such as the WHO IPCS definition of adverse 
effects. Without an apparent clear reference point for what is adverse or not it is not possible to 
determine whether a substance meets the WHO IPCS definition of ED or whether it does not 
meet such a definition. 
 
The significance of this proposed classification with regard to international trade is that, because 
it is not based on an a robust analysis and documentation of the scientific data demonstrating that 
DEHP, DBP, DIBP and BBP are endocrine disruptors according to the WHO IPCS definition, it 
americanchemistry.com®                                  700 Second St., NE | Washington, DC  20002 | (202) 249.7000                                                                       


could lead to inconsistent and very different regulatory conclusions in different regions leading 
to the disruption of trade of articles made with these substances and thereby constitute a barrier 
to trade. For example for endocrine disruptors it has been proposed that a no safe threshold 
approach would be applied on a blanket basis; this would lead to certain countries or regions 
banning the import of articles containing those substances based on the application of a non-
robust scientific standard.  
  
If this non-robust weight of evidence scientific evaluation approach is more broadly applied in 
the assessment of endocrine disruptors, this could result in major impacts on trade. For example, 
agricultural produce can also be impacted by such scientifically unjustified assessments, since 
crop protection agents, which may be present as residues in foodstuffs and which could 
considered as endocrine disruptors under EU regulation. This would impact international trade of 
such produce being impacted through restrictions and bans, particularly if a no threshold 
approach is applied. In view of these potential trade impacts it essential that robust scientific 
standards of evaluation and assessment are rigorously applied in determining which substances 
are and which substances are not endocrine disruptors. Without such an approach there will be 
widely differing conclusions in different regulatory jurisdictions with the associated confusion, 
chaos and impact on trade. 
 
Specific comments on the text from the European Commission 
The following statement from the European Commission text is particularly concerning as it 
states that multiple listing of the same substance for the same adverse effects but different modes 
of action is not precluded by REACH: 
 
“(10) The Commission notes further that Article 57 does not preclude identifying a 
substance as being of very high concern based on the same effect on human health 
several times, in order to specify the mode of action.” 

 
The objective of REACH is to provide a high level of protection for health and the environment, 
which surely means identifying potential adverse health and environmental effects and assessing 
the risks associated with such effects. The statement from the European Commission has 
significant implications with regard to regulatory duplication and the efficient use of resources, if 
the same substance can be listed repeatedly for the same adverse effect but different potential 
modes of action. It is important to note that double listing creates the obligation for companies 
that have already gone through the REACH Authorization process once to apply again for 
Authorization, with the significant costs and administrative burden that this process implies and 
the likely negative impact on the import of these substances and their use in many applications, 
which would further impact the business of foreign companies importing these substances into 
the EU. Additionally, the double listing gives scope for the EU to further strengthen restrictions 
on these substances in articles, which would directly impact non-European companies’ ability to 
sell their products and final articles made with the substances in question in the EU.   
 
Double listing and duplication of regulatory requirements also have implications with respect to 
the use of animals and animal welfare considerations, since such requirements could drive 
companies and regulators towards additional animal testing. With respect to international trade it 
also places demands on other regulatory jurisdictions to consider multiple modes of action for 
americanchemistry.com®                                  700 Second St., NE | Washington, DC  20002 | (202) 249.7000                                                                       


the same substance for the same adverse effect, with the associated impacts for regulatory 
duplication and the efficient use of resources.  
 
We would also note the following statements in the text: 
“According to four members of the MSC the effects for human health pointed out in the 
Annex XV dossiers were the same effects, caused by the same mode of action, as those 
already taken into account when the substances were included in the candidate list due to 
their toxicity for reproduction according to Article 57(c) of that Regulation.” 
 
“The Commission also notes that the majority of members of the MSC considered that the 
level of concern of those effects is equivalent.” 

 
In a committee which operates on a consensus basis to a significant degree it is relatively unusual 
for members to oppose proposals in this formal manner. The fact that four Member States 
opposed the double listing of the four LMW phthalates for the same adverse effect is very 
notable, and this point should be given much greater weight by the European Commission rather 
than dismissed as a minority. In the voting it should also be noted that five Member States 
abstained. The following point should also be noted (extract of the minutes of the ECHA MSC 
meeting of December 8 – 11, 2014): 
 
“Referring to the minority position arguments presented after the vote, several MSC 
members raised concerns that new elements were introduced, particularly regarding Risk 
Assessment Committee (RAC) deliberations, which were not raised during the MSC 
discussions. These members expressed a concern that by introducing the link to RAC at 
such a late stage, MSC was denied an in-depth scientific discussion on these objections.” 

 
 
americanchemistry.com®                                  700 Second St., NE | Washington, DC  20002 | (202) 249.7000